Skip to content

Safety of Tigecycline on Hematological System in Patients with Bacterial Infection: a Multicenter Open-label Trial

Safety of Tigecycline on Hematological System in Patients with Bacterial Infection: a Multicenter Open-label Trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058994
Enrollment
Unknown
Registered
2022-04-22
Start date
2022-04-20
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious diseases

Interventions

Sponsors

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 90 Years

Inclusion criteria

Inclusion criteria: 1.Severe patients with complex intra-abdominal infection, complex skin and soft tissue infection, community-acquired pneumonia and patients with multidrug-resistant Acinetobacter baumannii infection (excluding central nervous system and urinary tract infection) and carbapenem resistant Enterobacteriaceae infection (excluding central nervous system and urinary tract infection); 2.Men and women are not limited.

Exclusion criteria

Exclusion criteria: 1. The patient has had coagulation system disease in this admission; 2. Incomplete case data; 3. Those who are allergic to the drugs involved; 4. Treatment for less than 3 days.

Design outcomes

Primary

MeasureTime frame
Fibrinogen;Plasma prothrombin time;Activated partial thromboplastin time;platelet;

Secondary

MeasureTime frame
albumin;Alanine aminotransferase;Aspartate aminotransferase;total bilirubin;creatinine;

Countries

China

Contacts

Public ContactBing Leng

Shandong Provincial Hospital Affiliated to Shandong First Medical University

taozilb@163.com13791008771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026